Yehuda Zisapel
Angel Investor
Yehuda Zisapel is a Series A investor focused on Medical Device and Medical. Yehuda Zisapel is the co-founder of Red Biomed accelerator.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Yehuda Zisapel invests in
Stages Yehuda Zisapel invests in
Countries Yehuda Zisapel invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical Device 3 (43%)
- Medical 2 (29%)
- Health Care 2 (29%)
- Banking 1 (14%)
- FinTech 1 (14%)
Stage
- Series A 2 (29%)
- Funding Round 2 (29%)
- Seed 1 (14%)
- Series B 1 (14%)
- Venture - Series Unknown 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Rewire is a fintech startup that develops cross-border online banking solutions to provide the accessibility of financial services to migrants.The company's customer base includes migrated immigrants from Europe from over 20 countries in Asia and Africa such as the Philippines, Nigeria, India, Thailand, and China. With the help oftechnology, strategic partnerships, and values of equality, inclusivity, and social good, Rewire is able to provide financial services to make immigrants feel at home by integrating banking services into its platform and provide global accounts to its customers. To boost its cross-border solution, besides offering remittance services, payment accounts, and debit cards, Rewire plans to add new value-added services to its platforms such as bill payments and insurance, in addition to credit and loan services, investments, and savings. With these services, Rewire is able to make its first-rate financial services more accessible to migrants and, thus, include them in the financial systems. Investors OurCrowd, Renegade Partners, Glilot Capital Partners, AME Cloud Ventures, Viola Fintech, BNP Paribas, and Moneta Capital backs the fintech startup.Rewire was founded by Guy Kashtan, Saar Yahalom, Adi Ben Dayan, and Or Benoz in Tel Aviv, Tel Aviv in 2015. | $25M / Venture - Series Unknown / Feb 08, 2022 | ||
| Autonomous Low Speed Vehicle | $6.5M / Seed / Sep 20, 2020 | ||
| Laminate Medical Technologies is developing a new, external support device for AV fistulas, to be implanted during the fistula creation surgical procedure. The VasQ Device alleviates wall tension and regulates fistula geometry where an undesired narrowing of the vein and/or frequent blockages of the blood vessels may occur during the firstyear. Use of Laminate Medical Technology’s novel device aims to drive a change in the hemodialysis vascular access treatment paradigm and bring about a significant reduction in the annual fistula failure rate, thereby reducing kidney-failure related complications, re-interventions, and the cost burden of vascular access complications. | $8M / Series B / Feb 08, 2017 | ||
| Vectorious Medical Technologies developed the V-LAP, the worlds first in-heart microcomputer which enables optimal treatment for heart failure patients, increasing their quality of life and life expectancy. The V-LAP sensory implant is the first digital, wireless, battery-less device that is able to communicate from deep within the body. Itmonitors the heart’s left atrium pressure (LAP) which has been proven to be the earliest, most accurate and effective predictor for heart failure deterioration. Vectorious is actively conducting clinical studies in Europe (Italy, Germany, UK and Israel) for the purpose of obtaining a CE mark. It is expected to launch a clinical study in the US in 2020. | $5M / Series A / Feb 26, 2015 | ||
| Commex Technologies, Ltd., a fabless chip company, provides data-routing solutions for x86 multicore systems in Israel. It develops and sells in-server content-aware solutions, including the Vulcan family of 10GbE smart network interface cards (NICs). The company offers Vulcan SP HT6210 NIC that enables smart load balancing between servers, as wellas within-server CPU core load balancing for applications, such as network monitoring, application delivery, information technology (IT) security, bandwidth management, Web caching, database, Web 2.0, financial services, and media streaming. It also provides Vulcan SE HT6210 NIC for applications, including AFEs and ADCs, Web, telecom, automated trading, and data center; and Thunder network controllers to empower servers to withstand increased load and handle more service requests within a lower power envelope. In addition, Commex Technologies provides storage, streaming media, transaction, and Web server solutions. The company serves telecom, financial services, media and entertainment, storage, manufacturing, and distribution industries. Commex Technologies, Ltd. was founded in 2005 and is based in Tel Aviv, Israel. | Series A / Mar 31, 2009 | ||
| Commex Technologies, Ltd., a fabless chip company, provides data-routing solutions for x86 multicore systems in Israel. It develops and sells in-server content-aware solutions, including the Vulcan family of 10GbE smart network interface cards (NICs). The company offers Vulcan SP HT6210 NIC that enables smart load balancing between servers, as wellas within-server CPU core load balancing for applications, such as network monitoring, application delivery, information technology (IT) security, bandwidth management, Web caching, database, Web 2.0, financial services, and media streaming. It also provides Vulcan SE HT6210 NIC for applications, including AFEs and ADCs, Web, telecom, automated trading, and data center; and Thunder network controllers to empower servers to withstand increased load and handle more service requests within a lower power envelope. In addition, Commex Technologies provides storage, streaming media, transaction, and Web server solutions. The company serves telecom, financial services, media and entertainment, storage, manufacturing, and distribution industries. Commex Technologies, Ltd. was founded in 2005 and is based in Tel Aviv, Israel. | Mar 18, 2009 | ||
| BioLineRx is a clinical-stage, publicly-traded (NASDAQ/ TASE: BLRX) biopharmaceutical development company based in Jerusalem, Israel. The Company develops products suitable for the pharmaceutical market satisfying an unmet medical need or exhibiting advantages over current therapies. | $4M / May 04, 2004 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Yehuda Zisapel invest in?
Yehuda Zisapel invests primarily in Medical Device, Medical and Health Care startups, most often at Series A and Funding Round stage. Most of the 7 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Yehuda Zisapel?
Public channels for Yehuda Zisapel include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Yehuda Zisapel last invest?
The most recent investment recorded for Yehuda Zisapel closed in Feb 2022. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
